Drugs / mRNA-1020
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05333289 | Apr → Nov 2022 | influenza | ModernaTX, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-1020 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05333289 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA-1020 and mRNA-1030 Candidate Seasonal Influenza Vaccines” NCT05333289 ↗ |